Aptevo highlights bispecific pipeline; first AML patient shows 90% blast reduction

Aptevo Therapeutics Inc.

First patient in Phase 1b/2 RAINIER trial for mipletamig achieved 90% leukemic blast reduction within 30 days.
ALG.APV-527 Phase 1 data: 9 of 16 evaluable patients (56%) achieved stable disease; safety and tolerability positive.
Preclinical candidates APVO711, APVO603, APVO442 target PD-L1/CD40, 4-1BB/OX40, PSMA/CD3 respectively.
Company plans to add another targeted asset to pipeline in near-term but provides no details.
No financial updates or guidance provided; no leadership or corporate changes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.